,,iii  #aah? ,,congress  #a/ ,session   
,s4 ,,res4 #cfi  ,,9 ,,! ,,s5ate ,,( ,,!
 ,,unit$ ,,/ates  ,septemb] #bf         
7legislative day1 ,septemb] #bb71       
#bjbc,mr4 ,book] 7= ,mr4 ,scott ( ,s\?  
,c>ol9a 7= himself1 ,mr4 ,book]1 ,mr4   
,w>nock1 ,mr4 ,lank=d1 ,mr4 ,br[n1 ,mr4 
,rubio1 ,ms4 ,/ab5[1 ,mr4 ,"y1 ,mrs4    
,fe9/e91 ,mrs4 ,hyde-,smi?1 ,mr4        
,padilla1 ,mr4 ,c>p]1 & ,ms4 ,w>r577    
submitt$ ! foll[+ resolution2 :i* 0     
consid]$ & agre$ to  ,,resolution       
,express+ support = ! designation (     
,septemb] #bjbc z ,sickle ,cell ,disease
 ,aw>5ess ,mon? 9 ord] to educate       
communities across ! ,unit$ ,/ates ab\t 
sickle cell disease & ! ne$ = rese>*1   
e>ly detection me?ods1 effective        
treatm5ts1 & prev5tative c>e programs ) 
respect to complications f sickle cell  
disease & conditions relat$ to sickle   
cell disease4  ,:]eas sickle cell       
disease 7ref]r$ to 9 ?is preamble z     
,,scd7 is an inh]it$ blood disord] t is 
a major heal? problem 9 ! ,unit$ ,/ates 

& worldwide2 ,:]eas ,,scd causes ! rapid
 de/ruction ( sickle cells1 :i* results 
9 multiple m$ical complications1 includ+
 anemia1 jaundice1 gall/ones1 /rokes1   
re/rict$ blood fl[1 damag$ tissue 9 !   
liv]1 sple51 & kidneys1 & dea?2 ,:]eas  
,,scd causes acute & *ronic episodes (  
sev]e pa92 ,:]eas ,,scd affects an      
e/imat$ #ajj1jjj individuals 9 ! ,unit$ 
,/ates2 ,:]eas approximately #a1jjj     
babies are born ) ,,scd ea* ye> 9 !     
,unit$ ,/ates1 ) ! disease occurr+ 9    
approximately #a 9 #cfe newborn ,black  
or ,african-,am]ican infants & #a 9     
#af1cjj newborn ,hispanic-,am]ican      
infants1 & c be f\nd 9 individuals (    
,m$it]ranean1 ,middle ,ea/]n1 ,asian1 & 
,indian orig92 ,:]eas m ?an #c1jjj1jjj  
individuals 9 ! ,unit$ ,/ates h ! sickle
 cell trait & #a 9 #ac ,black or        
,african ,am]icans c>ries ! trait2      
,:]eas !re is a #a 9 #d *ance t a *ild  
born to p>5ts :o bo? h ! sickle cell    
trait w h ! disease2 ,:]eas ! life      
expectancy ( an individual ) ,,scd 9 !  

,unit$ ,/ates is (t5 sev]ely limit$2    
,:]eas sickle cell anemia c %ort5 life  
expectancy by m ?an #bj ye>s2 ,:]eas    
sickle cell anemia is a common cause (  
*ildhood /roke1 &1 9 #bjai1 few] ?an    
half ( *ildr5 ) sickle cell anemia :o 7 
#b to #af ye>s old receiv$ ! recomm5d$  
scre5+ = /roke2 ,:]eas1 9 #bjai1 only #b
 9 #e *ildr5 ) sickle cell anemia :o 7  
#b to #i ye>s old us$ recomm5d$         
m$ication t c prev5t sickle cell anemia 
complications2 ,:]eas1 9 #bjbj1 !       
,national ,academies ( ,sci5ce1         
,eng9e]+1 & ,m$ic9e develop$ a          
compreh5sive /rategic plan & bluepr9t = 
action to address sickle cell disease1  
:i*1 among o!r ?+s1 cit$ ! ne$ = new    
innovative !rapies z well z ! ne$ to    
address b>ri]s t may impact deliv]y ( & 
access to approv$ treatm5ts2 ,:]eas1    
:ile hematopoietic /em cell             
transplantation 7commonly kn[n z ,,hsct7
 is curr5tly ! only cure = ,,scd &      
advances 9 treat+ ! associat$           
complications ( ,,scd h occurr$1 m      

rese>* is ne$$ to f9d widely available  
treatm5ts & cures to help individuals ) 
,,scd2 & ,:]eas ,septemb] #bjbc has be5 
designat$ z ,sickle ,cell ,disease      
,aw>5ess ,mon? 9 ord] to educate        
communities across ! ,unit$ ,/ates ab\t 
,,scd1 includ+ e>ly detection me?ods1   
effective treatm5ts1 & prev5tative c>e  
programs ) respect to complications f   
,,scd & conditions relat$ to ,,scd3 ,n[1
 !re=e1 be x ,t ! ,s5ate-- 7#a7 supports
 ! goals & ideals ( ,sickle ,cell       
,disease ,aw>5ess ,mon?2 &  7#b7        
enc\rages ! p ( ! ,unit$ ,/ates to hold 
appropriate programs1 ev5ts1 &          
activities dur+ ,sickle ,cell ,disease  
,aw>5ess ,mon? to raise public aw>5ess (
 ! sickle cell trait1 prev5tative c>e   
programs1 treatm5ts1 & o!r pati5t       
s]vices = ^? suff]+ f sickle cell       
disease1 complications f sickle cell    
disease1 & conditions relat$ to sickle  
cell disease4